A nationwide coalition working to advance health equity and eliminate barriers to care and treatment for obesity and other chronic diseases.
- Tweets 557
- Following 40
- Followers 1,024
- Likes 50
Medicare Open Enrollment starts today.
1.1 million seniors have already signed up for Medicare's GLP-1 Bridge: obesity treatment for $50 a month. That's how much people need it.
Now make it permanent, and extend it to everyone left out. #MedicareOpenEnrollment #GLP1
2
5
6
185
New Mexico's adult obesity rate is 36.3% and has been the fastest rising of any state over the past decade.
While Medicare patients can now get GLP-1s for $50 a month, patients on Turquoise Care – New Mexico’s Medicaid program – still can't. @MANANational’s Lorena Blanco-Silva on why lawmakers should fix that in January: santafenewmexican.com/opinio…
1
2
30
HECCD is proud to stand with advocates fighting for obesity care in Massachusetts. Cutting GLP-1 coverage for MassHealth patients and state employees widens health gaps and raises long-term costs. Restoring coverage is the right thing to do for Bay Staters.
Obesity is a chronic disease. Treating it is a serious health access issue. When patients lose coverage for treatment, access gaps grow wider. We stand alongside stakeholders and advocates to discuss obesity care in Massachusetts.
Learn more at obesityassociation.org.
71
Gov. Pritzker has lost 80 pounds on a GLP-1 and calls it "life-changing." But millions of Medicaid enrollees, many from Black, Latino, and low-income communities, still can't get these FDA-approved treatments. Medicaid coverage of obesity medications should be the law in every state. Your income shouldn't decide your health.
chicago.suntimes.com/illinoi…
1
35
More employers are dropping GLP-1 coverage for weight loss, and patients are paying the price. Many are turning to compounded versions not by choice, but because approved treatment is out of reach. Obesity is a chronic disease. Coverage should treat it like one.
Read more from @Bloomberg: bloomberg.com/news/articles/…
50
September is National Healthy Aging Month. Part of aging well is affording the care you need. Fortunately, the Medicare GLP-1 Bridge gives eligible Part D beneficiaries FDA-approved weight-loss medication for $50.
Check out our fact sheet to learn more: healthequityaction.org/issue…
1
43
Patients deserve protection from dangerous, unregulated weight loss drugs, not a gamble on unproven and potentially unsafe alternatives.
Unapproved medications are fueling a wave of unregulated compounded knockoffs.
The FDA needs to act to protect patients, especially the most vulnerable. More from @axios: axios.com/2026/08/24/unappro…
39
Rural communities, Black communities and Latino communities, and low-income seniors have waited longest for affordable obesity care. The Medicare GLP-1 Bridge is a real step forward — $50/month for eligible beneficiaries.
healthequityaction.org/wp-co…
34
Too many people have gone without effective obesity treatment simply because of cost. That's starting to change. The Medicare GLP-1 Bridge program gives eligible beneficiaries access to FDA-approved GLP-1 medications for $50 a month.
If you're not sure whether you qualify, read our fact sheet to learn more. healthequityaction.org/wp-co…
1
66
GLP-1s can be life changing for people with obesity and diabetes, but Black and Latino Californians are getting far fewer prescriptions despite greater need.
The Governor’s decision to roll back Medi-Cal coverage for weight-loss drugs last year is only widening the gap.
Read more: latimes.com/opinion/story/20…
43
State Medicaid programs are cutting GLP-1 coverage across the country, leaving the most vulnerable patients without access to the affordable treatments they need.
A new @wapo article shows it is communities of color who pay the price when policy fails. washingtonpost.com/health/20…
1
38
High costs shouldn't leave patients feeling like risky alternatives are their only option.
@councilbh released a social media toolkit on the danger of drug compounding & the importance of FDA-approved GLP-1s.
Share this with your network to amplify their message. councilbh.org/drug-compoundi…
31
The rise of unregulated compounded drugs doesn't affect everyone equally. Communities with lower rates of insurance coverage and those already priced out of FDA-approved medications often face the greatest risks.
We stand with The Partnership for Safe Medicines on their call to strengthen patient safety protections.
Read the full report: insidehealthpolicy.com/login…
28
Obesity isn’t a lifestyle choice. It’s a chronic disease that raises the risk of heart disease, stroke, diabetes, and more. But Medicare beneficiaries living with obesity could not access care.
Starting today, that has changed. The Medicare GLP-1 Bridge Program is here. Read on:
1
61
We agree with Dr. Ambrose: Obesity is a chronic disease — not a lifestyle failure. And Pennsylvanians deserve access to treatment.
Pennsylvania cut Medicaid coverage for obesity medications and now Black and brown communities especially are paying the price.
We must fix this. inquirer.com/opinion/comment…
2
52
Unregulated compounded GLP-1s are putting patients at risk — especially in communities already underserved and overlooked by the healthcare system. HECCD has submitted a letter urging the FDA to finalize the removal of semaglutide, tirzepatide, and liraglutide from the bulk substances list.
Read HECCD’s statement: healthequityaction.org/news-…
56
The FDA just raised the alarm on compounded GLP-1 drugs. From unsanitary facilities to dosing errors leading to hospitalizations, there’s no replacement for FDA-approved care.
Millions of Americans turn to these risky alternatives every day because FDA-approved treatments aren't permanently covered by Medicaid or Medicare. It’s past time to change that. Join us in our fight to expand access to anti-obesity drugs.
healthequityaction.org/wp-co…
30
We’re calling on you to help urge CA policymakers to restore Medi-Cal coverage for obesity medications, including GLP-1 therapies, that help reduce health disparities among vulnerable groups. Cutting access to proven treatments is a health equity issue.
➡️Sign the petition: votervoice.net/DIABETES/Peti…
23